Atreca Inc (PK:BCEL)

Apr 17, 2024 07:45 pm ET
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BCEL, CTLT, NS, SCX
NEW YORK, April 17, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:
Jan 16, 2024 08:31 am ET
Thinking about buying stock in Carrols Restaurant Group, Atreca Inc, Energy Transfer, Agenus, or Recursion Pharmaceuticals?
NEW YORK, Jan. 16, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TAST, BCEL, ET, AGEN, and RXRX.
Dec 26, 2023 12:53 pm ET
BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
Halper Sadeh LLC, an investor rights law firm, is investigating whether Atreca, Inc.’s (NASDAQ: BCEL) definitive asset purchase agreement with Immunome, Inc. to sell a collection of antibody-related assets and materials is fair to Atreca shareholders. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones.
Dec 26, 2023 08:30 am ET
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into...
Nov 14, 2023 04:30 pm ET
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial...
Sep 21, 2023 08:00 am ET
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that, as...
Aug 10, 2023 04:05 pm ET
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Jun 05, 2023 08:00 am ET
Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced that Dr....
May 10, 2023 04:05 pm ET
Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Apr 26, 2023 04:05 pm ET
Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Apr 13, 2023 08:00 am ET
Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that...
Mar 29, 2023 04:05 pm ET
Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Mar 23, 2023 05:00 pm ET
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Mar 01, 2023 08:00 am ET
Atreca to Participate at Cowen’s 43rd Annual Health Care Conference
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that...
Feb 06, 2023 08:00 am ET
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, and Xencor, Inc....
Jan 09, 2023 08:30 am ET
Atreca Appoints Philippe Bishop, MD as Chief Medical Officer
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the...
Nov 10, 2022 04:30 pm ET
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of...
Nov 07, 2022 04:30 pm ET
Atreca to Present at Upcoming Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Oct 05, 2022 04:05 pm ET
Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two...
Sep 09, 2022 04:05 pm ET
Atreca to Present at Upcoming Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Aug 08, 2022 04:05 pm ET
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Aug 02, 2022 04:30 pm ET
Atreca to Present at Upcoming Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Jun 16, 2022 04:05 pm ET
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the...
Jun 01, 2022 04:01 pm ET
Atreca Announces Corporate Reorganization to Extend Cash Runway
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a...
May 19, 2022 04:30 pm ET
Atreca to Present at Upcoming Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
May 11, 2022 08:00 am ET
Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
May 04, 2022 04:30 pm ET
Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101”
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the...
Apr 08, 2022 04:05 pm ET
Atreca to Present at Upcoming Virtual Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that...
Apr 05, 2022 04:01 pm ET
Atreca Announces Expansion of Preclinical Pipeline
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a...
Mar 23, 2022 08:00 am ET
Atreca to Host Virtual R&D Day on Tuesday, April 5, 2022
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced it will...
Mar 09, 2022 08:31 am ET
Thinking about buying stock in Eos Energy Enterprises, Norwegian Cruise Line, Marathon Digital, Clovis Oncology, or Atreca?
NEW YORK, March 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EOSE, NCLH, MARA, CLVS, and BCEL.
Mar 04, 2022 08:30 am ET
Atreca to Participate in Cowen 42nd Annual Healthcare Conference
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that...
Mar 03, 2022 04:01 pm ET
Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Feb 24, 2022 04:30 pm ET
Atreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Jan 04, 2022 04:30 pm ET
Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Nov 08, 2021 04:30 pm ET
Atreca to Present at Upcoming Virtual Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Nov 02, 2021 08:30 am ET
Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Oct 21, 2021 08:00 am ET
Atreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of Malaria   
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Oct 01, 2021 08:00 am ET
Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two...
Sep 08, 2021 04:30 pm ET
Atreca to Present at Upcoming Virtual Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Aug 11, 2021 04:05 pm ET
Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Aug 04, 2021 04:30 pm ET
Atreca to Present at Upcoming Virtual Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Jul 29, 2021 07:00 am ET
Atreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid Tumors
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced initial...
Jul 26, 2021 04:30 pm ET
Atreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced it will...
Jul 19, 2021 04:30 pm ET
Atreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady to its Board of Directors
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the...
May 14, 2021 08:30 am ET
Atreca to Present at Upcoming Virtual Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at...
May 13, 2021 07:30 am ET
Atreca Reports First Quarter 2021 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Apr 06, 2021 04:30 pm ET
Atreca to Present at Upcoming Virtual Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will...
Mar 10, 2021 04:30 pm ET
Atreca Announces Poster Presentation at the Virtual American Association for Cancer Research (AACR) Annual Meeting
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a...
Feb 25, 2021 04:05 pm ET
Atreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Feb 22, 2021 04:30 pm ET
Atreca to Participate at Upcoming Virtual Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Nov 12, 2020 08:30 am ET
Atreca Reports Third Quarter 2020 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Nov 06, 2020 08:30 am ET
Atreca to Present at Upcoming Virtual Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will...
Oct 14, 2020 04:30 pm ET
Atreca Announces Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two...
Sep 03, 2020 08:00 am ET
Atreca to Present at Two Upcoming Virtual Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will...
Aug 12, 2020 08:30 am ET
Atreca Reports Second Quarter 2020 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Aug 05, 2020 04:30 pm ET
Atreca to Present at Two Upcoming Virtual Healthcare Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Jul 16, 2020 12:06 am ET
Atreca, Inc. Announces Pricing of Underwritten Public Offering of Common Stock
Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its previously...
Jul 15, 2020 04:01 pm ET
Atreca, Inc. Announces Proposed Underwritten Public Offering of Class A Common Stock
Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced that it intends to offer shares of...
Jul 08, 2020 08:01 am ET
Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, and Xencor, Inc....
Jul 08, 2020 08:01 am ET
Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell engaging bispecific antibodies as potential therapeutics in oncolo
Jun 11, 2020 08:00 am ET
Atreca Announces Webinar to Present ATRC-101 Preclinical Data Update on Monday, June 15, 2020
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that...
May 21, 2020 08:00 am ET
Atreca Announces Appointment of Kristine M. Ball to its Board of Directors
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of...
May 14, 2020 04:30 pm ET
Atreca Reports First Quarter 2020 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
May 13, 2020 05:00 pm ET
Atreca Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a...
May 12, 2020 04:30 pm ET
Atreca Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that management will...
Apr 06, 2020 04:30 pm ET
Atreca Announces Participation in Two Upcoming Virtual Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will...
Mar 12, 2020 05:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atreca, Inc. - BCEL
Pomerantz LLP is investigating claims on behalf of investors of Atreca, Inc. (“Atreca” or the “Company”) (NASDAQ: BCEL).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Mar 11, 2020 04:30 pm ET
Atreca Reports Fourth Quarter and Full Year 2019 Financial Results
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced...
Feb 24, 2020 04:30 pm ET
Atreca to Present at the Cowen and Company 40th Annual Health Care Conference
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that John Orwin, Chief...
Feb 13, 2020 04:30 pm ET
Atreca Announces First Patient Dosed in Phase 1b Clinical Trial of ATRC-101 in Patients with Select Solid Tumors
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the first patient...
Feb 05, 2020 04:05 pm ET
Atreca Announces Strategic Research Collaboration with Merck to Identify Novel Antibody Targets in Oncology
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it...
Dec 03, 2019 08:00 am ET
Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the...
Nov 14, 2019 08:00 am ET
Atreca to Present at Two Upcoming Investor Conferences
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced that it will present at two upcoming investor conferences: Stifel...
Nov 12, 2019 04:05 pm ET
Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial results for the third quarter ended September 30, 2019, and...
Nov 05, 2019 08:00 am ET
Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced that it will present a poster describing preclinical evaluations of...
Aug 26, 2019 04:05 pm ET
Atreca Announces Appointment of Dr. Lindsey Rolfe to its Board of Directors
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, to the...
Aug 13, 2019 04:05 pm ET
Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial results for the second quarter ended June 30, 2019, and...
Jul 11, 2019 08:00 am ET
Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel
Atreca, Inc. (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lisa L. Decker, Ph.D., as Chief Business Officer and...
Jun 19, 2019 09:40 pm ET
Atreca Announces Pricing of Initial Public Offering
Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its initial public...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.